HLVX Stock Price, HilleVax, Inc. Quote, Chart

Market Summary

USD15.54-0.03

Delayedas of 17 May 2024, 11:58 am

-0.19%

HLVX Alerts

1 major insider buys recently.

HLVX Stock Price

View Fullscreen

HLVX RSI Chart

HLVX Valuation

Market Cap

774.2M

Price/Earnings (Trailing)

-5.39

Price/Free Cashflow

-6.93

HLVX Price/Earnings (Trailing)

HLVX Profitability

Return on Equity

-60.07%

Return on Assets

-45.68%

Free Cashflow Yield

-14.43%

HLVX Fundamentals

HLVX Earnings

Earnings (TTM)

-143.5M

Earnings Growth (Yr)

-74.16%

Earnings Growth (Qtr)

-26.7%

Breaking Down HLVX Revenue

52 Week Range

11.3518.98

(Low)(High)

Last 7 days

11.1%

Last 30 days

19.5%

Last 90 days

1.4%

Trailing 12 Months

5.6%

How does HLVX drawdown profile look like?

HLVX Financial Health

Current Ratio

10.92

Debt/Equity

0.11

Debt/Cashflow

-4.08

HLVX Investor Care

Shares Dilution (1Y)

26.84%

Diluted EPS (TTM)

-3.3

Tracking the Latest Insider Buys and Sells of HilleVax, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 03, 2024	kohli aditya	sold	-10,233	14.1542	-723	-
May 02, 2024	kohli aditya	sold	-84,081	14.0135	-6,000	-
May 01, 2024	kohli aditya	sold	-2,456	14.0343	-175	-
Apr 05, 2024	kohli aditya	sold	-86,640	14.44	-6,000	-
Apr 04, 2024	frazier life sciences x, l.p.	bought	128,325	14.5	8,850	-
Apr 04, 2024	kohli aditya	sold	-88,245	14.7075	-6,000	-
Apr 03, 2024	kohli aditya	sold	-89,581	14.9303	-6,000	-
Mar 28, 2024	mcloughlin sean	bought	21,225	16.98	1,250	chief operating officer
Mar 20, 2024	kohli aditya	sold	-985,326,000	164,221	-6,000	-
Mar 19, 2024	kohli aditya	sold	-104,492	17.4153	-6,000	-

Which funds bought or sold HLVX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Tudor Investment Corp Et Al	unchanged	-	10,280	294,750	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-77.81	-30,355	9,063	-%
May 15, 2024	Woodline Partners LP	new	-	315,804	315,804	-%
May 15, 2024	ACUTA CAPITAL PARTNERS, LLC	reduced	-22.79	-1,042,200	4,167,630	2.71%
May 15, 2024	Deep Track Capital, LP	reduced	-11.29	-3,764,990	42,780,000	1.23%
May 15, 2024	Frazier Life Sciences Management, L.P.	unchanged	-	5,673,250	162,666,000	6.86%
May 15, 2024	T. Rowe Price Investment Management, Inc.	added	110	27,583,000	50,917,000	0.03%
May 15, 2024	BRAIDWELL LP	sold off	-100	-3,264,680	-	-%
May 15, 2024	VR Adviser, LLC	unchanged	-	1,203,500	34,507,200	1.64%
May 15, 2024	D. E. Shaw & Co., Inc.	new	-	468,284	468,284	-%

Are Funds Buying or Selling HLVX?

Are funds buying HLVX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HLVX

No. of Funds

HLVX Alerts

1 major insider buys recently.

Unveiling HilleVax, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ra capital management, l.p.	0%	0	SC 13G/A
Feb 14, 2024	lightspeed venture partners select iv, l.p.	4.8%	2,303,871	SC 13G/A
Feb 14, 2024	deep track capital, lp	5.99%	2,900,000	SC 13G/A
Feb 12, 2024	flynn james e	4.38%	2,121,577	SC 13G/A
Feb 12, 2024	carlyle group inc.	3.8%	1,838,486	SC 13G/A
Sep 29, 2023	deep track capital, lp	6.14%	2,900,000	SC 13G
Sep 27, 2023	frazier life sciences public fund, l.p.	2.6%	1,246,135	SC 13D/A
May 05, 2023	frazier life sciences public fund, l.p.	3.2%	1,246,135	SC 13D/A
Feb 14, 2023	ra capital management, l.p.	5.3%	1,760,019	SC 13G
Feb 10, 2023	flynn james e	2.43%	811,447	SC 13G/A

Recent SEC filings of HilleVax, Inc.

View All Filings

Date Filed	Form Type	Document
May 09, 2024	EFFECT	EFFECT
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 03, 2024	4	Insider Trading
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 12, 2024	PRE 14A	PRE 14A
Apr 08, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading

HilleVax, Inc. News

Latest updates

HilleVax, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet										(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-8.8%	314	344	367	287	301	317	322	341	115	127
Current Assets	-9.5%	281	311	333	253	270	291	300	320	112	125
Cash Equivalents	-34.9%	141	217	209	158	261	279	292	315	111	125
Net PPE	-3.0%	14.00	14.00	14.00	13.00	10.00	6.00	1.00	-	-	0.00
Liabilities	-4.6%	75.00	79.00	68.00	68.00	58.00	50.00	35.00	38.00	283	228
Current Liabilities	-12.0%	26.00	29.00	19.00	18.00	19.00	13.00	9.00	13.00	283	228
Long Term Debt	0.8%	25.00	25.00	25.00	25.00	15.00	15.00	5.00	5.00	-	-
LT Debt, Non Current	-100.0%	-	25.00	25.00	25.00	15.00	15.00	5.00	5.00	-	-
Shareholder's Equity	-10.0%	239	266	299	219	243	267	287	303	-	-100
Retained Earnings	-12.1%	-435	-388	-351	-319	-291	-264	-243	-227	-173	-105
Additional Paid-In Capital	3.1%	675	655	651	539	535	532	531	530	5.00	4.00
Shares Outstanding	2.9%	49.00	48.00	47.00	38.00	38.00	38.00	24.00	27.00	7.00	7.00
Float	-	-	-	-	258	-	-	-	228	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)													(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Cashflow From Operations	-52.7%	-33,002	-21,606	-26,806	-22,417	-15,954	-18,517	-19,547	-13,210	-10,715	-4,194	-1,565	-1,119	-417
Share Based Compensation	38.3%	5,194	3,756	3,946	3,246	2,642	1,331	844	556	272	-	-	-	-
Cashflow From Investing	-295.7%	-57,662	29,469	-31,174	-89,948	-2,985	-3,829	-185	-	-2,500	-	-	-	-
Cashflow From Financing	4712.1%	15,062	313	108,107	10,198	80.00	9,687	-2,820	218,201	-99.00	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

HLVX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development (includes related party amounts of $27 and $168, respectively)	$ 25,978	$ 23,164
In-process research and development	15,325
General and administrative (includes related party amounts of $0 and $3, respectively)	8,494	5,795
Total operating expenses	49,797	28,959
Loss from operations	(49,797)	(28,959)
Other income (expense):
Interest income	2,402	2,574
Interest expense	(727)	(449)
Other income (expense)	1,293	(55)
Total other income	2,968	2,070
Net loss	(46,829)	(26,889)
Other comprehensive income (loss):
Unrealized loss on marketable securities	(121)
Pension and other postemployment benefits	78	(1)
Total comprehensive loss	$ (46,872)	$ (26,890)
Net loss per share, basic	$ (0.97)	$ (0.71)
Net loss per share, diluted	$ (0.97)	$ (0.71)
Weighted-average shares of common stock outstanding, basic	48,460,185	37,753,522
Weighted-average shares of common stock outstanding, diluted	48,460,185	37,753,522

HLVX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 141,076	$ 216,678
Marketable securities	131,667	86,805
Prepaid expenses and other current assets (includes related party amounts of $77 and $0, respectively)	8,355	7,195
Total current assets	281,098	310,678
Property and equipment, net	13,592	14,018
Operating lease right-of-use assets	17,831	18,082
Restricted cash	1,631	1,631
Other assets	23	25
Total assets	314,175	344,434
Current liabilities:
Accounts payable	2,980	7,461
Accrued expenses (includes related party amounts of $27 and $33, respectively)	19,143	18,553
Accrued interest	135	134
Current portion of operating lease liability	3,491	3,118
Total current liabilities	25,749	29,266
Operating lease liability, net of current portion	22,364	22,831
Long-term debt, net of debt discount	25,453	25,244
Other long-term liabilities	1,700	1,568
Total liabilities	75,266	78,909
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock, $0.0001 par value; authorized shares- 50,000,000 at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.0001 par value; authorized shares-500,000,000 at March 31, 2024 and December 31, 2023; issued shares- 49,718,443 and 48,497,853 at March 31, 2024 and December 31, 2023, respectively; outstanding shares-49,055,192 and 47,666,438 at March 31, 2024 and December 31, 2023, respectively	5	5
Additional paid-in capital	675,242	654,986
Accumulated other comprehensive loss	(950)	(907)
Accumulated deficit	(435,388)	(388,559)
Total stockholders' equity	238,909	265,525
Total liabilities and stockholders' equity	$ 314,175	$ 344,434

About HilleVax, Inc.

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

CEO	Dr. Robert M. Hershberg M.D., Ph.D.
WEBSITE	hillevax.com
INDUSTRY	Biotechnology
EMPLOYEES	62

HilleVax, Inc. Frequently Asked Questions

What is the ticker symbol for HilleVax, Inc.? What does HLVX stand for in stocks?

HLVX is the stock ticker symbol of HilleVax, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of HilleVax, Inc. (HLVX)?

As of Thu May 16 2024, market cap of HilleVax, Inc. is 774.16 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HLVX stock?

You can check HLVX's fair value in chart for subscribers.

What is the fair value of HLVX stock?

You can check HLVX's fair value in chart for subscribers. The fair value of HilleVax, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of HilleVax, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HLVX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is HilleVax, Inc. a good stock to buy?

The fair value guage provides a quick view whether HLVX is over valued or under valued. Whether HilleVax, Inc. is cheap or expensive depends on the assumptions which impact HilleVax, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HLVX.